InMed Pharmaceuticals (NASDAQ: INM) shares fiscal 2025 results

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. filed a current report to note that on September 23, 2025 it announced financial results for its fiscal year ending June 30, 2025 and gave a business update. The update covered its pharmaceutical drug development programs and the commercial segment of its wholly owned subsidiary, BayMedica, LLC. The related news release is furnished as Exhibit 99.1 under a Regulation FD disclosure and is not deemed filed or incorporated by reference unless specifically stated in another filing.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/23/2025 - 05:24 PM Learn about SEC filing dates

FAQ

What did InMed Pharmaceuticals (INM) disclose in this 8-K filing?

InMed Pharmaceuticals disclosed that on September 23, 2025 it announced financial results for its fiscal year ending June 30, 2025 and provided a business update on its pharmaceutical drug development programs and the commercial segment of its wholly owned subsidiary, BayMedica, LLC.

Which period do the reported InMed Pharmaceuticals (INM) results cover?

The financial results discussed in the announcement relate to InMed Pharmaceuticals’ fiscal year ending June 30, 2025.

How is the information in InMed Pharmaceuticals’ 8-K treated under the Exchange Act?

The information provided under Item 7.01, including Exhibit 99.1, is being furnished and not filed for purposes of Section 18 of the Exchange Act and is not subject to its liabilities, nor is it incorporated by reference into other filings unless specifically referenced.

What exhibit did InMed Pharmaceuticals (INM) include with this 8-K?

InMed Pharmaceuticals included Exhibit 99.1, described as a news release dated September 23, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Which subsidiary of InMed Pharmaceuticals is mentioned in the business update?

The business update references the commercial segment of InMed’s wholly owned subsidiary BayMedica, LLC.

On which exchange are InMed Pharmaceuticals common shares listed?

InMed Pharmaceuticals’ common shares, with no par value, trade under the symbol INM on The Nasdaq Stock Market LLC.

false 0001728328 A1 0001728328 2025-09-23 2025-09-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 23, 2025

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

InMed Pharmaceuticals Inc. Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada		V6C 3E8
(Address of Principal Executive Offices)		(Zip Code)

Company’s telephone number, including area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 7.01 Regulation FD Disclosure.

On September 23, 2025, the Company announced financial results for its fiscal year ending June 30, 2025 and provided a business update on its pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC (“BayMedica”).

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		News release, dated September 23, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED PHARMACEUTICALS INC.
Date: September 23, 2025	By:	/s/ Eric A Adams
		Eric A Adams
		President & CEO

2